Guilford Paclimer

Executive Summary

IND filing for paclitaxel injection product expected by year-end for ovarian cancer treatment. Paclimer's delivery system reduces the need for the high concentrations of paclitaxel in Bristol-Myers Squibb's Taxol that cause side effects, the company said. Paclimer would only require one or two injections during a 16-week period. Pre-clinical results of paclitaxel vs. Paclimer (4 mg/kg in both arms) showed 10% survival for paclitaxel at 120 days compared to 50% for Paclimer. At 40 mg/kg, paclitaxel showed 60% survival at 120 days compared to 90% for Paclimer